Mochida Pharmaceutical
Biosimilar developer, Japan. 5 development products across 5 molecules: adalimumab, etanercept, pegfilgrastim, teriparatide, tocilizumab.
First approval in the Atlas: Jan 2018, Etanercept BS MA, etanercept (PMDA)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved5
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Adalimumab BS MA | · | · | Mar 2021 | · | · | · |
| Etanercept | Etanercept BS MA LBEC0101 | · | · | Jan 2018 | · | · | · |
| Pegfilgrastim | Pegfilgrastim BS Mochida / Nipro | · | · | Sep 2023 | · | · | · |
| Teriparatide | Teriparatide BS Mochida | · | · | Sep 2019 | · | · | · |
| Tocilizumab | Tocilizumab BS MA | · | · | Mar 2026 | · | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Mochida Pharmaceutical is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Filgrastim | Filgrastim BS F / Mochida | PMDA | Fuji Pharma; Mochida Pharmaceutical | Nov 2012 | Fuji Pharma (with Mochida) |
Chronology
- PMDAJan 2018Etanercept BS MA, etanercept
- PMDASep 2019Teriparatide BS MOCHIDA, teriparatide
- PMDAMar 2021Adalimumab BS MA, adalimumab
- PMDASep 2023Pegfilgrastim BS Mochida / Nipro, pegfilgrastim
- PMDAMar 2026Tocilizumab BS MA, tocilizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.